UQ leads the State in NHMRC grants

October 11, 2005

University of Queensland researchers have been awarded more than $22 million as part of the latest round of National Health and Medical Research Council (NHMRC) Project Grant funding announced yesterday (October 10).

UQ's share of the funding ($22,224,648) was the largest in Queensland and made up more than half the total Queensland funding. It included funding for a UQ researcher working on developing a drug to block the growth of fat cells.

Of the 85 projects funded in Queensland for health and medical research, UQ was successful in 45, confirming the University's place as the top research institution in the State and one of the nation's leaders.

Nationally, UQ was fifth behind the University of Melbourne ($42,704,750), the University of Sydney ($31,313,298), the University of Western Australia ($27,186,979) and Monash University ($24,092,363).

UQ's Deputy Vice-Chancellor (Research) Professor David Siddle said he was pleased with the University's performance, which saw an increase in research funding by more than $6 million from 2004.

"Our researchers have done very well and there are some terrific success stories in these results," Professor Siddle said.

UQ's Dr Louise Hutley was awarded $422,625 for her work on a drug to block the growth of fat cells

The School of Medicine researcher is working on a project entitled FGF-1 In Development of Human Obesity.

Obesity is a major contributor to medical conditions including Type 2 Diabetes, cardiovascular disease, cancer and depression.

"Despite the fact that obesity is so prevalent in our society we still don't really know what makes fat tissue grow," Dr Hutley said.

Using human fat tissue Dr Hutley has identified a growth factor crucial to the development of fat cells.

"These findings form the basis of novel therapies that will target and block development of new fat cells, thus limiting growth of fat tissue, Dr Hutley said.

The largest UQ award was a massive $1,841,500, which went to Professor Tom Gonda, Dr Brian Gabrielli, Dr Sean Grimmond and Dr Simon Barry from UQ's Centre for Immunology and Cancer Research for their study into Retroviral Expression Cloning Using Arrayed Full Length cDNA Gene Set.

Dr Gabrielli said the money would be used to form the Arrayed Retroviral Expression Cloning Facility, the only one of its kind in the Southern Hemisphere and one of the first in the world.

"The project will enable us to look at the function of every gene in the human genome," he said.

"It has applications in just about every biological process including cancer, neurological diseases and metabolic diseases."

Another significant award to UQ was the $980,250 for Professor Jennifer Stow's projects, one of which is with Dr Rohan Teasdale on Protein Activation in Tumour Cells.

Professor Stow, from UQ's Institute for Molecular Bioscience, will investigate how proteins reach their proper location in the cell and the implications of these processes for cancer and inflammatory diseases.

In particular, her current research looks at the protein known as E-cadherin, which prevents tumour cells from multiplying, but in malignant tumours, this protein malfunctions allowing cancerous tumour cells to spread. This research will help better understand why this protein fails to activate in malignant tumour cells.

"The grant means we can start to explore new areas, using imaging in live cells to find out how tumour suppressors are regulated in cells and possibly how they can be manipulated to stop cells turning into cancer cells," Professor Stow said.

Professor Stow also received an NHMRC Fellowship, brining her total awards to $1.6million.
-end-
Media: For more information or to arrange interviews, contact Chris Saxby at UQ Communications (telephone +61 733 652 479, email c.saxby@uq.edu.au).

Research Australia

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.